VANCOUVER, Nov. 14 /PRNewswire-FirstCall/ -- Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) has scheduled a conference call and web cast for Monday, November 17, 2003 at 9:00 a.m. ET (6:00 a.m. PT) to discuss results from the Phase IIb clinical trial of MBI 594AN. It is anticipated that the results of the trial will be released prior to the conference call.
About the Conference Call
To participate in the conference call, please dial 416-405-9328 or 1-800- 387-6216. The call will be available for replay until December 1, 2003 by calling 1-800-408-3053 or 416-695-5800 and entering the pass code 1498266. The live or archived web cast can be accessed through the company's website at http://www.mbiotech.com/.
About Micrologix
Micrologix Biotech Inc. is engaged in the research, development, and commercialization of drugs that advance therapy, improve health, and enrich lives. The Company's focus is toward anti-infective drug development with three product candidates in human clinical studies, multiple product opportunities in preclinical development, and several early-stage technologies in various stages of research and evaluation.
Investor & Media Relations Contacts:
Jonathan Burke
Micrologix Biotech Inc.
Telephone: 604.221.9666 Extension 241
Toll-Free: 1.800.665.1968
E-mail: jburke@mbiotech.com
Shayne Payne/Dian Griesel, Ph.D
The Investor Relations Group
Telephone: 212-825-3210
Email: theproteam@aol.com
Micrologix Biotech Inc.
CONTACT: Investor & Media Relations Contacts: Jonathan Burke, MicrologixBiotech Inc., Telephone: 604-221-9666 Extension 241, Toll-Free:1-800-665-1968, E-mail: jburke@mbiotech.com; Shayne Payne/Dian Griesel,Ph.D, The Investor Relations Group, Telephone: 212-825-3210, Email:theproteam@aol.com;To request a free copy of this organization's annual report, please go tohttp://www.newswire.ca/ and click on reports@cnw.